David Moreno-Martínez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David Moreno-Martínez has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Sara Lucas Del Pozo
Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London (UCL), London, UK
4 shared publications - Derralynn A. Hughes
Lysosomal Storage Disorders Unit, Royal Free London NHS Foundation Trust and University College London
3 shared publications - Jorge Hernández-Vara
Hospital Universitario Vall d’Hebron, 08035 Barcelona, Spain
3 shared publications - Guillem Pintos-Morell
Clinical Biochemistry Drug Delivery and Therapy Group (CB-DDT), Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Barcelona 08035, Spain
2 shared publications - Lucia Lavalle
Lysosomal Storage Disorders Unit Royal Free Hospital NHS Foundation Trust and University College London London UK
2 shared publications - Maria Camprodon-Gomez
Department of Internal Medicine, Unit of Hereditary Metabolic Disorders, Vall d’Hebron University Hospital, Barcelona, Spain
2 shared publications
Latest Publications
- Open Access
- 14 March 2026
- Published by Elsevier in SSRN Electronic Journal
Mitochondrial Unfolded Protein Response Activation Associates with Phenotypes in Fabry Disease
Background: Fabry disease (FD) exhibits marked clinical heterogeneity that cannot be fully explained by residual α-galactosidase A activity. Mitochondrial dysfunction has been reported in FD, but the role of mitochondrial stress remains unexplored.Objective: To investigate whether activation of the mitochondrial unfolded protein response contributes to phenotypic variability and correlates with disease severity.Methods: We measured intracellular heat-shock protein 60 (Hsp60) by western blotting in peripheral blood mononuclear cells from 27 FD patients (14 males, 13 females). Serum fibroblast growth-factor-21 and growth differentiation-factor-15 were measured in 35 patients. Clinical outcomes included Mainz Severity Score Index, Age-Adjusting Severity Score, estimated glomerular filtration rate, and left-ventricular mass index (LVMI).Results: Hsp60 showed variability, with sex-specific associations. In males, higher Hsp60 correlated with lower LVMI (r²=-0.82, p=0.01) and preserved renal function in late-onset patients (r²=0.89, p=0.006). In females, higher Hsp60 associated with higher LVMI (r²=0.66, p=0.045) and greater clinical severity. Male patients had elevated growth differentiation-factor-15 vs controls (935 vs 559 pg/ml, p=0.002). Both mitokines correlated with age and disease severity.Conclusions: mitochondrial unfolded protein response activation exhibits sex- and genotype-specific patterns associated with disease severity, suggesting that mitochondrial stress contributes to phenotypic heterogeneity and may serve as biomarkers for treatment optimisation.
- 14 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMitochondrial Unfolded Protein Response Activation Associates with Phenotypes in Fabry Disease
Background: Fabry disease (FD) exhibits marked clinical heterogeneity that cannot be fully explained by residual α-galactosidase A activity. Mitochondrial dysfunction has been reported in FD, but the role of mitochondrial stress remains unexplored.Objective: To investigate whether activation of the mitochondrial unfolded protein response contributes to phenotypic variability and correlates with disease severity.Methods: We measured intracellular heat-shock protein 60 (Hsp60) by western blotting in peripheral blood mononuclear cells from 27 FD patients (14 males, 13 females). Serum fibroblast growth-factor-21 and growth differentiation-factor-15 were measured in 35 patients. Clinical outcomes included Mainz Severity Score Index, Age-Adjusting Severity Score, estimated glomerular filtration rate, and left-ventricular mass index (LVMI).Results: Hsp60 showed variability, with sex-specific associations. In males, higher Hsp60 correlated with lower LVMI (r²=-0.82, p=0.01) and preserved renal function in late-onset patients (r²=0.89, p=0.006). In females, higher Hsp60 associated with higher LVMI (r²=0.66, p=0.045) and greater clinical severity. Male patients had elevated growth differentiation-factor-15 vs controls (935 vs 559 pg/ml, p=0.002). Both mitokines correlated with age and disease severity.Conclusions: mitochondrial unfolded protein response activation exhibits sex- and genotype-specific patterns associated with disease severity, suggesting that mitochondrial stress contributes to phenotypic heterogeneity and may serve as biomarkers for treatment optimisation.
- Open Access
- 7 November 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (11) , e70415
Stroke in Fabry Disease: Identification of Risk Factors for Stroke in a Large Single‐Centre Cohort
Objectives: Risk factors for stroke in Fabry disease (FD) are not precisely known. This study presents a retrospective cohort analysis from one reference centre in the United Kingdom to determine risk factors for stroke and to develop a predictive model. Methods: Patients > 18 years old were included in the study and were followed from their first visit until March 2019. The main outcome of the survival analysis was time to stroke. The independent risk factors were evaluated using a multivariate Cox regression. Results: Of 414 patients, 368 were included in the survival analysis. 227 (61.7%) were female, with a median baseline age of 42.7 (IQR 27.8–54.8) for males and 39.9 (26.6–51.2) years for females. 56 (39.7%) males and 64 (28.2%) females had the N215S genotype. 41 patients had a stroke at baseline (11.2%), rising to 69 (18.8%) at the end—66.7% lacunar, 18.9% anterior circulation, 13% posterior circulation and 1.4% venous thrombosis. Median follow‐up was 10.4 years. Median time to stroke in males and females was 43 (43–43) and 58 (58–59) years, respectively. In the multivariate analysis, a concomitant autoimmune disease was associated with an increased risk of stroke, while glomerular filtration rate > 90 and N215S genotype were associated with a decreased risk. Interpretation: Sex was not associated with stroke, despite males being more severe. These results might help stratify patients and are of interest not only to metabolic physicians, but to general stroke physicians too.
- 7 November 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (11) , e70415
Open AccessStroke in Fabry Disease: Identification of Risk Factors for Stroke in a Large Single‐Centre Cohort
Objectives: Risk factors for stroke in Fabry disease (FD) are not precisely known. This study presents a retrospective cohort analysis from one reference centre in the United Kingdom to determine risk factors for stroke and to develop a predictive model. Methods: Patients > 18 years old were included in the study and were followed from their first visit until March 2019. The main outcome of the survival analysis was time to stroke. The independent risk factors were evaluated using a multivariate Cox regression. Results: Of 414 patients, 368 were included in the survival analysis. 227 (61.7%) were female, with a median baseline age of 42.7 (IQR 27.8–54.8) for males and 39.9 (26.6–51.2) years for females. 56 (39.7%) males and 64 (28.2%) females had the N215S genotype. 41 patients had a stroke at baseline (11.2%), rising to 69 (18.8%) at the end—66.7% lacunar, 18.9% anterior circulation, 13% posterior circulation and 1.4% venous thrombosis. Median follow‐up was 10.4 years. Median time to stroke in males and females was 43 (43–43) and 58 (58–59) years, respectively. In the multivariate analysis, a concomitant autoimmune disease was associated with an increased risk of stroke, while glomerular filtration rate > 90 and N215S genotype were associated with a decreased risk. Interpretation: Sex was not associated with stroke, despite males being more severe. These results might help stratify patients and are of interest not only to metabolic physicians, but to general stroke physicians too.
- Open Access
- 25 March 2024
- Published by OAE Publishing Inc. in Rare Disease and Orphan Drugs Journal
- Vol. 3 (1)
Cerebrovascular disorders and Fabry disease
Fabry disease (FD) is an X-linked lysosomal storage disorder caused by pathogenic variants in the GLA gene encoding for alpha-galactosidase A. Renal, cardiac, and cerebrovascular involvement are the leading complications in early adulthood and are associated with severe morbidity and mortality. Cerebrovascular manifestations in FD manifest as ischemic stroke and transient ischemic attack and less frequently as hemorrhagic strokes. Many patients may develop their stroke not only before other major complications but also before the diagnosis of FD is made. This review will describe the frequency and characteristics of cerebrovascular disease in FD, the complex pathophysiological mechanisms, the neuroimaging findings, the value of screening studies in young patients with stroke, and the controversies regarding the beneficial effect of ERT for the prevention of cerebrovascular disease in FD.
- 25 March 2024
- Published by OAE Publishing Inc. in Rare Disease and Orphan Drugs Journal
- Vol. 3 (1)
Open AccessCerebrovascular disorders and Fabry disease
Fabry disease (FD) is an X-linked lysosomal storage disorder caused by pathogenic variants in the GLA gene encoding for alpha-galactosidase A. Renal, cardiac, and cerebrovascular involvement are the leading complications in early adulthood and are associated with severe morbidity and mortality. Cerebrovascular manifestations in FD manifest as ischemic stroke and transient ischemic attack and less frequently as hemorrhagic strokes. Many patients may develop their stroke not only before other major complications but also before the diagnosis of FD is made. This review will describe the frequency and characteristics of cerebrovascular disease in FD, the complex pathophysiological mechanisms, the neuroimaging findings, the value of screening studies in young patients with stroke, and the controversies regarding the beneficial effect of ERT for the prevention of cerebrovascular disease in FD.
- Open Access
Phenotypic effect of GBA1 variants in individuals with and without Parkinson disease: the RAPSODI study
Background: Variants in the GBA1 gene cause the lysosomal storage disorder Gaucher disease (GD). They are also risk factors for Parkinson disease (PD), and modify the expression of the PD phenotype. The penetrance of GBA1 variants in PD is incomplete, and the ability to determine who amongst GBA1 variant carriers are at higher risk of developing PD, would represent an advantage for prognostic and trial design purposes. Objectives: To compare the motor and non-motor phenotype of GBA1 carriers and non-carriers. Methods: We present the cross-sectional results of the baseline assessment from the RAPSODI study, an online assessment tool for PD patients and GBA1 variant carriers. The assessment includes clinically validated questionnaires, a tap-test, the University of Pennsyllvania Smell Identification Test and cognitive tests. Additional, homogeneous data from the PREDICT-PD cohort were included. Results: A total of 379 participants completed all parts of the RAPSODI assessment (89 GBA1 -negative controls, 169 GBA1 -negative PD, 47 GBA1 -positive PD, 47 non-affected GBA1 carriers, 27 GD). Eightysix participants were were recruited through PREDICT-PD (43 non-affected GBA1 carriers and 43 GBA1 -negative controls). GBA1 -positive PD showed worse performance in visual cognitive tasks and olfaction compared to GBA1 -negative PD patients. No differences were detected between non-affected GBA1 carriers carriers and GBA1 -negative controls. No phenotypic differences were observed between any of the non-PD groups. Conclusions: Our results support previous evidence that GBA1 -positive PD has a specific phenotype with more severe non-motor symptoms. However, we did not reproduce previous findings of more frequent prodromal PD signs in non-affected GBA1 carriers.
Open AccessPhenotypic effect of GBA1 variants in individuals with and without Parkinson disease: the RAPSODI study
Background: Variants in the GBA1 gene cause the lysosomal storage disorder Gaucher disease (GD). They are also risk factors for Parkinson disease (PD), and modify the expression of the PD phenotype. The penetrance of GBA1 variants in PD is incomplete, and the ability to determine who amongst GBA1 variant carriers are at higher risk of developing PD, would represent an advantage for prognostic and trial design purposes. Objectives: To compare the motor and non-motor phenotype of GBA1 carriers and non-carriers. Methods: We present the cross-sectional results of the baseline assessment from the RAPSODI study, an online assessment tool for PD patients and GBA1 variant carriers. The assessment includes clinically validated questionnaires, a tap-test, the University of Pennsyllvania Smell Identification Test and cognitive tests. Additional, homogeneous data from the PREDICT-PD cohort were included. Results: A total of 379 participants completed all parts of the RAPSODI assessment (89 GBA1 -negative controls, 169 GBA1 -negative PD, 47 GBA1 -positive PD, 47 non-affected GBA1 carriers, 27 GD). Eightysix participants were were recruited through PREDICT-PD (43 non-affected GBA1 carriers and 43 GBA1 -negative controls). GBA1 -positive PD showed worse performance in visual cognitive tasks and olfaction compared to GBA1 -negative PD patients. No differences were detected between non-affected GBA1 carriers carriers and GBA1 -negative controls. No phenotypic differences were observed between any of the non-PD groups. Conclusions: Our results support previous evidence that GBA1 -positive PD has a specific phenotype with more severe non-motor symptoms. However, we did not reproduce previous findings of more frequent prodromal PD signs in non-affected GBA1 carriers.
- Open Access
- 1 August 2021
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 8 (S1) , S37-S39
Galactosemia Diagnosis by Whole Exome Sequencing Later in Life
- 1 August 2021
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 8 (S1) , S37-S39
Open AccessGalactosemia Diagnosis by Whole Exome Sequencing Later in Life
- Open Access
- 13 April 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (8) , 1664
Biomarkers in Fabry Disease. Implications for Clinical Diagnosis and Follow-up
Fabry disease (FD) is a lysosomal storage disorder caused by deficient alpha-galactosidase A activity in the lysosome due to mutations in the GLA gene, resulting in gradual accumulation of globotriaosylceramide and other derivatives in different tissues. Substrate accumulation promotes different pathogenic mechanisms in which several mediators could be implicated, inducing multiorgan lesions, mainly in the kidney, heart and nervous system, resulting in clinical manifestations of the disease. Enzyme replacement therapy was shown to delay disease progression, mainly if initiated early. However, a diagnosis in the early stages represents a clinical challenge, especially in patients with a non-classic phenotype, which prompts the search for biomarkers that help detect and predict the evolution of the disease. We have reviewed the mediators involved in different pathogenic mechanisms that were studied as potential biomarkers and can be easily incorporated into clinical practice. Some accumulation biomarkers seem to be useful to detect non-classic forms of the disease and could even improve diagnosis of female patients. The combination of such biomarkers with some response biomarkers, may be useful for early detection of organ injury. The incorporation of some biomarkers into clinical practice may increase the capacity of detection compared to that currently obtained with the established diagnostic markers and provide more information on the progression and prognosis of the disease.
- 13 April 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (8) , 1664
Open AccessBiomarkers in Fabry Disease. Implications for Clinical Diagnosis and Follow-up
Fabry disease (FD) is a lysosomal storage disorder caused by deficient alpha-galactosidase A activity in the lysosome due to mutations in the GLA gene, resulting in gradual accumulation of globotriaosylceramide and other derivatives in different tissues. Substrate accumulation promotes different pathogenic mechanisms in which several mediators could be implicated, inducing multiorgan lesions, mainly in the kidney, heart and nervous system, resulting in clinical manifestations of the disease. Enzyme replacement therapy was shown to delay disease progression, mainly if initiated early. However, a diagnosis in the early stages represents a clinical challenge, especially in patients with a non-classic phenotype, which prompts the search for biomarkers that help detect and predict the evolution of the disease. We have reviewed the mediators involved in different pathogenic mechanisms that were studied as potential biomarkers and can be easily incorporated into clinical practice. Some accumulation biomarkers seem to be useful to detect non-classic forms of the disease and could even improve diagnosis of female patients. The combination of such biomarkers with some response biomarkers, may be useful for early detection of organ injury. The incorporation of some biomarkers into clinical practice may increase the capacity of detection compared to that currently obtained with the established diagnostic markers and provide more information on the progression and prognosis of the disease.
- Open Access
- 1 January 2021
- Published by Elsevier in Neurología
- Vol. 36 (1) , 92-94
Ataxia por déficit de vitamina E en una familia con posible afectación cardíaca
- 1 January 2021
- Published by Elsevier in Neurología
- Vol. 36 (1) , 92-94
Open AccessAtaxia por déficit de vitamina E en una familia con posible afectación cardíaca